Statin effects on regulatory and proinflammatory factors in chronic idiopathic urticaria

Clinical and Experimental Immunology

Volumn 166, Issue 2, 2011, Pages 291-298

  Azor, M H ^a   dos Santos, J C ^a   Futata, E A ^a   de Brito, C A ^a   Maruta, C W ^a   Rivitti, E A ^a   da Silva Duarte, A J ^a   Sato, M N ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chronic idiopathic urticaria; Cytokines; Immunomodulation; Proinflammatory factors; Regulatory factors; Statins

Indexed keywords

CD14 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MEVINOLIN; PHYTOHEMAGGLUTININ; SIMVASTATIN; SUPERANTIGEN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL PROLIFERATION; CHRONIC URTICARIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; INNATE IMMUNITY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UPREGULATION;

ADAPTIVE IMMUNITY; ADULT; AGED; CELL CYCLE; CELL PROLIFERATION; CHEMOKINE CCL3; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNITY, INNATE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LOVASTATIN; MALE; MIDDLE AGED; PHYTOHEMAGGLUTININS; RNA, MESSENGER; SIMVASTATIN; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; URTICARIA; YOUNG ADULT;

EID: 80053646859     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04473.x     Document Type: Article

References (32)

1. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197-201.
2. Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol 2006; 30:47-51.
3. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328:1599-604.
4. Grattan CE. Basophils in chronic urticaria. J Invest Dermatol Symp Proc 2001; 6:139-40.
5. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009; 39:777-87.
6. Lourenco FD, Azor MH, Santos JC etal. Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus. Br J Dermatol 2008; 158:979-86.
7. Vonakis BM, Vasagar K, Gibbons SP etal. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 2007; 119:441-8.
8. Tedeschi A, Asero R, Lorini M, Marzano AV, Cugno M. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy 2010; 40:875-81.
9. Dos Santos JC, Azor MH, Nojima VY etal. Increased circulating pro-inflammatory cytokines and imbalanced regulatory T-cell cytokines production in chronic idiopathic urticaria. Int Immunopharmacol 2008; 8:1433-40.
10. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762-74.
11. Fallarino F, Grohmann U, Hwang KW etal. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4:1206-12.
12. Mellor AL, Munn DH. Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses. J Reprod Immunol 2001; 52:5-13.
13. Elliott J, Johnston JA. SOCS: role in inflammation, allergy and homeostasis. Trends Immunol 2004; 25:434-40.
14. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24:677-88.
15. Chen Z, O'Shea JJ. Regulation of IL-17 production in human lymphocytes. Cytokine 2008; 41:71-8.
16. Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, Preemptive NRS. HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007; 110:4588-98.
17. Mausner-Fainberg K, Luboshits G, Mor A etal. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008; 197:829-39.
18. Fehr T, Kahlert C, Fierz W etal. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004; 175:83-90.
19. Blanco-Colio LM, Martin-Ventura JL, Gomez-Hernandez A, Egido J. Statins, inflammation and atherosclerotic damage. Nefrologia 2004; 24:17-20.
20. Kuijk LM, Mandey SH, Schellens I etal. Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. Mol Immunol 2008; 45:2158-65.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8.
22. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 2008; 180:6988-96.
23. Neuhaus O, Strasser-Fuchs S, Fazekas F etal. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002; 59:990-7.
24. (+) T cells via inhibition of small guanosine triphosphatase (GTPase) activity and caspase-independent apoptosis. Clin Exp Immunol 2006; 146:524-32.
25. Samson KT, Minoguchi K, Tanaka A etal. Effect of fluvastatin on apoptosis in human CD4+ T cells. Cell Immunol 2005; 235:136-44.
26. Coward W, Chow SC. Effect of atorvastatin on TH1 and TH2 cytokine secreting cells during T cell activation and differentiation. Atherosclerosis 2006; 186:302-9.
27. Yilmaz A, Reiss C, Weng A etal. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol 2006; 79:529-38.
28. Piconi S, Trabattoni D, Iemoli E etal. Immune profiles of patients with chronic idiopathic urticaria. Int Arch Allergy Immunol 2002; 128:59-66.
29. Thomas SR, Salahifar H, Mashima R, Hunt NH, Richardson DR, Stocker R. Antioxidants inhibit indoleamine 2, 3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol 2001; 166:6332-40.
30. Yuan W, Collado-Hidalgo A, Yufit T, Taylor M, Varga J. Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine 2, 3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J Cell Physiol 1998; 177:174-86.
31. Orabona C, Pallotta MT, Volpi C etal. SOCS3 drives proteasomal degradation of indoleamine 2, 3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci USA 2008; 105:20828-33.
32. Terness P, Bauer TM, Rose L etal. Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002; 196:447-57.